Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689602 | 1.00 | KLK7 (0.49) | KLK7SLC18A2KCNH2OPRD1MEN1 | |
| SCHEMBL13086596 | 1.00 | KLK7 (0.49) | KLK7SLC18A2KCNH2OPRD1MEN1 | |
| SCHEMBL13086758 | 0.93 | MEN1 (0.50) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL13086595 | 0.92 | MEN1 (0.49) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL13086597 | 0.91 | MEN1 (0.48) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL6012084 | 0.91 | MEN1 (0.48) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL13086353 | 0.91 | MEN1 (0.48) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL20056683 | 0.90 | KLK7 (0.46) | KLK7OPRD1MEN1NPC1RAB9A | |
| SCHEMBL6917036 | 0.88 | ATM (0.44) | OPRD1NPC1NR1H2 | |
| SCHEMBL698422 | 0.87 | NR1H2 (0.54) | KLK7OPRD1MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261914-A1 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-10-14 | — | — | US | disclosed |
| US-7718600-B2 | IAP binding compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1578777-B1 | IAP BINDING COMPOUNDS | UNIV PRINCETON (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-02-08 | — | — | US | disclosed |
| EP-1578777-A4 | IAP BINDING COMPOUNDS | UNIV PRINCETON (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1578777-A2 | IAP BINDING COMPOUNDS | The Trustees of Princeton University (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004007529-A2 | IAP BINDING COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | BIRC3, API5, BID | KLK7 4561/4885SLC18A2 4466/4885KCNH2 4401/4885 |
| US-20100261914-A1 | IAP BINDING COMPOUNDS | BIRC3, BIRC5, BIRC2 | KLK7 4439/4885SLC18A2 4086/4885KCNH2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.